KN-026

Summary

Kn-026 (CHEMBL4594568) is a phase-3 clinical-stage unknown; indicated across 4 conditions including breast neoplasm and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594568
Name	KN-026
Type	Unknown
Max phase	3

Also known as: Anbenitamab, Anti-her2 bsab kn026, Kn 026, Kn-026, KN-026, Kn026, KN026

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
breast neoplasm	3	MONDO:0021100	MONDO:0007254
neoplasm	2	MONDO:0005070	EFO:0000616
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
adenocarcinoma	2	MONDO:0004970	MONDO:0003219

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE2	8
PHASE2/PHASE3	2
PHASE3	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05427383	PHASE2/PHASE3	RECRUITING	KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
NCT06747338	PHASE3	RECRUITING	A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
NCT07332533	PHASE2/PHASE3	NOT_YET_RECRUITING	A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
NCT07441460	PHASE3	RECRUITING	A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
NCT05985707	PHASE2	NOT_YET_RECRUITING	KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
NCT06023758	PHASE2	RECRUITING	Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
NCT06998771	PHASE2	NOT_YET_RECRUITING	JSKN003 Combined Treatment of HER2-positive Gastric Cancer
NCT07597629	PHASE2	NOT_YET_RECRUITING	A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
NCT03925974	PHASE2	COMPLETED	KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer
NCT04165993	PHASE2	UNKNOWN	Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer
NCT04521179	PHASE2	COMPLETED	Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
NCT04881929	PHASE2	UNKNOWN	Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
NCT03619681	PHASE1	COMPLETED	Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
NCT03847168	PHASE1	UNKNOWN	KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).